(PRI) Primerica - Overview
Sector: Financial Services | Industry: Insurance - Life | Exchange: NYSE (USA) | Market Cap: 8.419m USD | Total Return: 2% in 12m
Avg Turnover: 48.1M
EPS Trend: 99.6%
Qual. Beats: 3
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Primerica, Inc. (PRI) provides financial services specifically targeting middle-income households in the United States and Canada. The company operates through three primary segments: Term Life Insurance, Investment and Savings Products, and Corporate and Other Distributed Products. Its distribution model relies on a large network of licensed sales representatives to sell insurance, mutual funds, annuities, and various legal and identity protection services.
The company functions within the Life & Health Insurance industry, where a key business driver is the ability to generate recurring premium income while managing underwriting risks. Unlike many diversified financial firms that focus on high-net-worth clients, Primerica’s strategy centers on a high-volume, commission-based sales force to reach underserved demographic segments. Investors can further analyze these operational metrics and valuation trends on ValueRay.
Founded in 1927 and based in Duluth, Georgia, the firm also offers ancillary products such as mortgage loans and home automation solutions. This multi-product approach allows the company to capture multiple revenue streams from a single household client base.
- Rising interest rates boost yields on fixed-income portfolios and investment product demand
- Growth in licensed sales force headcount drives insurance policy issuance volume
- Middle-income consumer sentiment and disposable income levels impact investment product sales
- Regulatory changes to fiduciary standards increase compliance costs for independent sales representatives
- Term life insurance persistency rates directly influence long-term underwriting profitability and margins
| Net Income: 772.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.85 > 1.0 |
| NWC/Revenue: 100.5% < 20% (prev 131.9%; Δ -31.37% < -1%) |
| CFO/TA 0.06 > 3% & CFO 856.5m > Net Income 772.3m |
| Net Debt (-2.27b) to EBITDA (1.02b): -2.22 < 3 |
| Current Ratio: 5.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.7m) vs 12m ago -4.84% < -2% |
| Gross Margin: 62.05% > 18% (prev 57.41%; Δ 4.64% > 0.5%) |
| Asset Turnover: 22.74% > 50% (prev 21.65%; Δ 1.10% > 0%) |
| Interest Coverage Ratio: 18.95 > 6 (EBIT TTM 1.00b / Interest Expense TTM 52.9m) |
| A: 0.23 (Total Current Assets 4.09b - Total Current Liabilities 743.7m) / Total Assets 14.7b |
| B: 0.17 (Retained Earnings 2.44b / Total Assets 14.7b) |
| C: 0.07 (EBIT TTM 1.00b / Avg Total Assets 14.6b) |
| D: 0.21 (Book Value of Equity 2.52b / Total Liabilities 12.2b) |
| Altman-Z'' = 2.72 = A |
| DSRI: 0.08 (Receivables 280.2m/3.16b, Revenue 3.33b/3.16b) |
| GMI: 0.93 (GM 57.41% / 62.05%) |
| AQI: 1.09 (AQ_t 0.72 / AQ_t-1 0.66) |
| SGI: 1.05 (Revenue 3.33b / 3.16b) |
| TATA: -0.01 (NI 772.3m - CFO 856.5m) / TA 14.7b) |
| Beneish M = -3.76 (Cap -4..+1) = AAA |
As of June 07, 2026, the stock is trading at USD 265.84 with a total of 195,002 shares traded.
Over the past week, the price has changed by -1.53%,
over one month by -3.78%,
over three months by +1.06% and
over the past year by +1.97%.
Primerica has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold PRI.
- StrongBuy: 2
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 298.5 | 12.3% |
P/E Trailing = 11.3242
P/E Forward = 14.0449
P/S = 2.4644
P/B = 3.3409
P/EG = 1.0671
Revenue TTM = 3.33b USD
EBIT TTM = 1.00b USD
EBITDA TTM = 1.02b USD
Long Term Debt = 1.73b USD (from longTermDebt, last quarter)
Short Term Debt = 7.69m USD (from shortTermDebt, last fiscal year)
Debt = 1.82b USD (from shortLongTermDebtTotal, last quarter) + Leases 48.4m
Net Debt = -2.27b USD (calculated: Debt 1.82b - CCE 4.09b)
Enterprise Value = 6.15b USD (8.42b + Debt 1.82b - CCE 4.09b)
Interest Coverage Ratio = 18.95 (Ebit TTM 1.00b / Interest Expense TTM 52.9m)
EV/FCF = 5.66x (Enterprise Value 6.15b / FCF TTM 1.09b)
FCF Yield = 17.66% (FCF TTM 1.09b / Enterprise Value 6.15b)
FCF Margin = 32.65% (FCF TTM 1.09b / Revenue TTM 3.33b)
Net Margin = 23.20% (Net Income TTM 772.3m / Revenue TTM 3.33b)
Gross Margin = 62.05% ((Revenue TTM 3.33b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 80.87% (prev 80.76%)
Tobins Q-Ratio = 0.42 (Enterprise Value 6.15b / Total Assets 14.7b)
Interest Expense / Debt = 2.90% (Interest Expense 52.9m / Debt 1.82b)
Taxrate = 22.98% (230.4m / 1.00b)
NOPAT = 772.3m (EBIT 1.00b * (1 - 22.98%))
Current Ratio = 3.32 (Total Current Assets 4.09b / Total Current Liabilities 1.23b)
Debt / Equity = 0.72 (Debt 1.82b / totalStockholderEquity, last quarter 2.52b)
Debt / EBITDA = -2.22 (Net Debt -2.27b / EBITDA 1.02b)
Debt / FCF = -2.09 (Net Debt -2.27b / FCF TTM 1.09b)
Total Stockholder Equity = 2.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.28% (Net Income 772.3m / Total Assets 14.7b)
RoE = 32.28% (Net Income TTM 772.3m / Total Stockholder Equity 2.39b)
RoCE = 24.35% (EBIT 1.00b / Capital Employed (Equity 2.39b + L.T.Debt 1.73b))
RoIC = 5.37% (NOPAT 772.3m / Invested Capital 14.4b)
WACC = 6.96% (E(8.42b)/V(10.2b) * Re(7.98%) + D(1.82b)/V(10.2b) * Rd(2.90%) * (1-Tc(0.23)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -4.52%
[DCF] Terminal Value 77.97% ; FCFF base≈859.5m ; Y1≈985.3m ; Y5≈1.45b
[DCF] Fair Price = 772.5 (EV 21.8b - Net Debt -2.27b = Equity 24.1b / Shares 31.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.61 | EPS CAGR: 20.90% | SUE: 1.33 | # QB: 3
Revenue Correlation: 99.13 | Revenue CAGR: 7.86% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=5.93 | Chg30d=-0.45% | Revisions=-11% | Analysts=7
EPS next Quarter (2026-09-30): EPS=6.21 | Chg30d=-0.06% | Revisions=-11% | Analysts=7
EPS current Year (2026-12-31): EPS=24.50 | Chg30d=+2.50% | Revisions=+64% | GrowthEPS=+6.9% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=26.49 | Chg30d=+1.24% | Revisions=+60% | GrowthEPS=+8.1% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +64%